Author

H. Barr

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 2 Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:differential expression· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:clustering· 1

Frequent Co-Authors

A. Plotnikov· 3 shared N. London· 3 shared D. Zaidman· 2 shared E. Resnick· 2 shared F. von DelftiD· 2 shared A. Aimon· 1 shared A. Bradley· 1 shared A. C. Greenwald· 1 shared

Activity by Year

2018-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

A. Plotnikov

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Dual Targeting of Histone Deacetylases and MYC as Potential Treatment Strategy for H3-K27M Pediatric Gliomas

D. Algranati, R. Oren, B. Dassa, L. Fellus-Alyagor, A. Plotnikov, H. Barr, A. Harmelin, N. London, G. Ron, N. Furth, E. Shema

This study investigates dual targeting of HDACs and MYC in H3-K27M pediatric gliomas, showing synergistic effects in reducing cell viability and tumor growth.

bioRxiv · Feb 5, 2024Cancer Biology

An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.

D. Zaidman, P. Gehrtz, M. Filep, D. Fearon, J. Prilusky, S. Duberstein, G. Cohen, D. Owen, E. Resnick, C. Strain-Damerell, P. Lukacik, Covid-Moonshot Consortium, H. Barr, M. A. Walsh, F. von Delft, N. London

The paper introduces a computational pipeline to design irreversible inhibitors, identifying a potent SARS-CoV-2 Mpro inhibitor with low micromolar IC50.

Cell Chemical Biology · Dec 1, 2021Peer-reviewedBiochemistry

Pan-cancer single cell RNA-seq uncovers recurring programs of cellular heterogeneity

G. S. Kinker, A. C. Greenwald, R. Tal, Z. Orlova, M. S. Cuoco, J. M. McFarland, A. Warren, C. Rodman, J. A. Roth, S. A. Bender, B. Kumar, J. W. Rocco, P. A. Fernandes, C. C. Mader, H. Keren-Shaul, , I. Tirosh

The paper uses single-cell RNA-seq to analyze cancer cell lines and identifies recurring expression programs of heterogeneity that mirror those in tumors, suggesting intrinsic plasticity contributes to intra-tumoral diversity.

bioRxiv · Oct 21, 2019 · PreprintCancer Biology

Rapid covalent-probe discovery by electrophile fragment screening

e. resnick, A. Bradley, J. Gan, A. Douangamath, T. Krojer, R. Sethi, A. Aimon, G. Amitai, D. Belini, J. Bennett, M. Fairhead, O. Fedorov, P. P. Geurink, J. Guo, A. Plotnikov, , N. London

This study develops a method for discovering covalent probes using electrophile fragment screening and identifies selective inhibitors for OTUB2 and NUDT7.

bioRxiv · Oct 14, 2018Biochemistry